開拓藥業(9939.HK)拉昇漲超23% 市場看好新冠口服藥普克魯胺治療潛力
格隆匯4月8日丨開拓藥業-B(9939.HK)今日盤中再度拉昇漲超23%至26.85港元。公司4月6日公佈普克魯胺全球輕中症三期臨牀數據,反映顯著的療效訊號,且入組者不限受試者疫苗接種狀態,及基礎疾病等情況。公司並將在之後4-6周內進一步完成所有數據分析,並可能基於完整的數據結果向中國、美國、歐盟和其他國家監管機構遞交緊急使用授權(EUA)申請。消息公佈當天該股股價翻倍。招銀國際最新研報維持其買入評級,目標價由34.37港元上調至48.78港元,看好其新冠口服藥普克魯胺治療潛力。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.